Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Merck
Harvard Business School
Dow

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SAMSCA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Samsca

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01199198 Tolvaptan in Hyponatremic Cancer Patients Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 4 2011-05-01 The goal of this clinical research study is to learn if tolvaptan can help raise salt (sodium) levels in the cancer patients' blood by removing extra body water as urine.
NCT01199198 Tolvaptan in Hyponatremic Cancer Patients Completed M.D. Anderson Cancer Center Phase 4 2011-05-01 The goal of this clinical research study is to learn if tolvaptan can help raise salt (sodium) levels in the cancer patients' blood by removing extra body water as urine.
NCT01227512 Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Terminated Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2010-10-01 The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction. The study will also test if tolvaptan is better than fluid restriction in treating the symptoms of hyponatremia in hospitalized patients.
NCT01228682 Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice Unknown status Otsuka Frankfurt Research Institute GmbH N/A 2010-10-01 A Drug Utilisation Survey is performed to monitor and document the drug utilisation patterns of Samsca in routine medical practice. A Post-Authorisation Safety Study is performed to collect information on the safety of Samsca when used in a real-life setting.
NCT01261481 Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact Completed Otsuka America Pharmaceutical Phase 1 2011-01-01 The purpose of the study is to compare the relative bioavailability and pharmacokinetics of tolvaptan 15 mg tablets administered orally versus tolvaptan via nasogastric (NG) tube in healthy male and female subjects. This study is an open 2-treatment, 2-period, 2-sequence crossover study to compare the relative bioavailability of tolvaptan tablets to tolvaptan given via nasogastric tube in 28 healthy adults. Subjects will be randomized to one of the two treatment sequences; either tolvaptan oral tablets swallowed intact followed by a tablet crushed and administered via nasogastric tube, or the reverse sequence. Serial pharmacokinetic samples will be collected following each tolvaptan administration and safety assessments will be performed. The relative bioavailability of tolvaptan administered via nasogastric tube will be compared to tolvaptan tablets swallowed intact.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Samsca

Condition Name

Condition Name for Samsca
Intervention Trials
Hyponatremia 10
Heart Failure 5
Ascites 4
Hepatic Cirrhosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Samsca
Intervention Trials
Hyponatremia 13
Heart Failure 11
Ascites 5
Liver Cirrhosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Samsca

Trials by Country

Trials by Country for Samsca
Location Trials
United States 54
Germany 7
Denmark 5
Italy 4
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Samsca
Location Trials
North Carolina 5
California 3
Texas 3
Pennsylvania 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Samsca

Clinical Trial Phase

Clinical Trial Phase for Samsca
Clinical Trial Phase Trials
Phase 4 12
Phase 3 10
Phase 2 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Samsca
Clinical Trial Phase Trials
Completed 15
Recruiting 10
Unknown status 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Samsca

Sponsor Name

Sponsor Name for Samsca
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 7
Otsuka America Pharmaceutical 5
Otsuka Beijing Research Institute 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Samsca
Sponsor Trials
Other 39
Industry 22
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Dow
Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.